Forte Biosciences (FBRX) Competitors $7.34 +0.08 (+1.10%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$7.11 -0.23 (-3.13%) As of 04/17/2025 06:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock FBRX vs. PBYI, KRRO, CTNM, RAPT, TNGX, TARA, ACTU, LYEL, GLSI, and IKTShould you be buying Forte Biosciences stock or one of its competitors? The main competitors of Forte Biosciences include Puma Biotechnology (PBYI), Korro Bio (KRRO), Contineum Therapeutics (CTNM), RAPT Therapeutics (RAPT), Tango Therapeutics (TNGX), Protara Therapeutics (TARA), Actuate Therapeutics (ACTU), Lyell Immunopharma (LYEL), Greenwich LifeSciences (GLSI), and Inhibikase Therapeutics (IKT). These companies are all part of the "pharmaceutical products" industry. Forte Biosciences vs. Puma Biotechnology Korro Bio Contineum Therapeutics RAPT Therapeutics Tango Therapeutics Protara Therapeutics Actuate Therapeutics Lyell Immunopharma Greenwich LifeSciences Inhibikase Therapeutics Puma Biotechnology (NASDAQ:PBYI) and Forte Biosciences (NASDAQ:FBRX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, community ranking, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment. Which has stronger earnings & valuation, PBYI or FBRX? Puma Biotechnology has higher revenue and earnings than Forte Biosciences. Forte Biosciences is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPuma Biotechnology$230.47M0.62$21.59M$0.614.69Forte BiosciencesN/AN/A-$31.48M-$16.29-0.45 Is PBYI or FBRX more profitable? Puma Biotechnology has a net margin of 9.56% compared to Forte Biosciences' net margin of 0.00%. Puma Biotechnology's return on equity of 41.60% beat Forte Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Puma Biotechnology9.56% 41.60% 10.71% Forte Biosciences N/A -151.43%-118.92% Does the media prefer PBYI or FBRX? In the previous week, Forte Biosciences had 1 more articles in the media than Puma Biotechnology. MarketBeat recorded 3 mentions for Forte Biosciences and 2 mentions for Puma Biotechnology. Puma Biotechnology's average media sentiment score of 0.29 beat Forte Biosciences' score of -0.18 indicating that Puma Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Puma Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Forte Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, PBYI or FBRX? Puma Biotechnology has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500. Comparatively, Forte Biosciences has a beta of 2.52, indicating that its share price is 152% more volatile than the S&P 500. Does the MarketBeat Community favor PBYI or FBRX? Puma Biotechnology received 524 more outperform votes than Forte Biosciences when rated by MarketBeat users. Likewise, 67.27% of users gave Puma Biotechnology an outperform vote while only 62.00% of users gave Forte Biosciences an outperform vote. CompanyUnderperformOutperformPuma BiotechnologyOutperform Votes55567.27% Underperform Votes27032.73% Forte BiosciencesOutperform Votes3162.00% Underperform Votes1938.00% Do institutionals & insiders believe in PBYI or FBRX? 61.3% of Puma Biotechnology shares are owned by institutional investors. Comparatively, 77.6% of Forte Biosciences shares are owned by institutional investors. 23.7% of Puma Biotechnology shares are owned by company insiders. Comparatively, 3.1% of Forte Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Do analysts recommend PBYI or FBRX? Puma Biotechnology currently has a consensus price target of $7.00, suggesting a potential upside of 144.76%. Forte Biosciences has a consensus price target of $32.50, suggesting a potential upside of 342.78%. Given Forte Biosciences' higher probable upside, analysts clearly believe Forte Biosciences is more favorable than Puma Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Puma Biotechnology 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Forte Biosciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryPuma Biotechnology beats Forte Biosciences on 11 of the 16 factors compared between the two stocks. Get Forte Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for FBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FBRX vs. The Competition Export to ExcelMetricForte BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$48.31M$6.45B$5.30B$7.35BDividend YieldN/A3.23%5.12%4.30%P/E Ratio-0.456.8921.8017.80Price / SalesN/A231.03379.9697.74Price / CashN/A65.6738.2634.64Price / Book0.305.936.443.98Net Income-$31.48M$142.99M$3.21B$247.73M7 Day Performance39.81%4.42%2.87%1.81%1 Month Performance33.45%-12.73%-8.63%-6.98%1 Year PerformanceN/A-9.48%11.46%1.37% Forte Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FBRXForte Biosciences2.6049 of 5 stars$7.34+1.1%$32.50+342.8%+24,697.3%$48.31MN/A-0.455Options VolumePBYIPuma Biotechnology3.3417 of 5 stars$2.83-2.4%$7.00+147.3%-44.7%$140.40M$230.47M5.90200Analyst UpgradeKRROKorro Bio1.388 of 5 stars$14.93+3.8%$136.33+813.2%-79.9%$140.18M$2.27M-1.5970Analyst ForecastNews CoveragePositive NewsGap UpCTNMContineum Therapeutics2.1582 of 5 stars$5.37-7.4%$24.80+361.8%-70.0%$138.93M$50M-1.1031Positive NewsGap DownRAPTRAPT Therapeutics3.6138 of 5 stars$1.05-0.9%$4.00+281.0%-90.2%$138.61M$1.53M-0.3880Short Interest ↑News CoverageTNGXTango Therapeutics2.0971 of 5 stars$1.27flat$12.33+871.1%-82.7%$137.30M$42.07M-1.0890Analyst RevisionNews CoverageGap UpTARAProtara Therapeutics1.8158 of 5 stars$3.70-5.1%$22.50+508.1%+42.9%$136.04MN/A-1.3130Analyst ForecastNews CoveragePositive NewsGap UpACTUActuate TherapeuticsN/A$6.82-1.0%$20.00+193.3%N/A$133.21MN/A0.0010News CoverageLYELLyell Immunopharma3.1963 of 5 stars$0.45-3.9%$1.00+123.9%-81.8%$131.85M$61,000.00-0.57270Analyst ForecastGap DownGLSIGreenwich LifeSciences1.6036 of 5 stars$9.59+8.6%$38.00+296.2%-31.4%$126.06MN/A-11.993Earnings ReportUpcoming EarningsGap DownHigh Trading VolumeIKTInhibikase Therapeutics1.0446 of 5 stars$1.68-8.7%$6.50+286.9%-11.0%$124.90M$260,000.00-0.636Gap DownHigh Trading Volume Related Companies and Tools Related Companies PBYI Competitors KRRO Competitors CTNM Competitors RAPT Competitors TNGX Competitors TARA Competitors ACTU Competitors LYEL Competitors GLSI Competitors IKT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FBRX) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored‘Wheels Are Falling Off’ the U.S. Stock MarketThe last time the U.S. economy looked like this, stocks didn't move for 16 years... And many investors lost...Stansberry Research | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredTrump to unlock 15-figure fortune for America (May 3rd) ?Recently, President Trump decided to kill the coin, for good reason. It now costs 4 cents to make a single pen...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Forte Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Forte Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy FBRX Stock Free FBRX Stock Alerts